Goldman Sachs Group Reiterates “€77.00” Price Target for Bayer (BAYN)

Share on StockTwits

Bayer (FRA:BAYN) has been given a €77.00 ($89.53) price objective by equities research analysts at Goldman Sachs Group in a report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s target price suggests a potential upside of 36.40% from the company’s current price.

Several other research firms have also recently weighed in on BAYN. UBS Group set a €110.00 ($127.91) price target on Bayer and gave the stock a “buy” rating in a report on Thursday, March 28th. Baader Bank set a €123.00 ($143.02) price target on Bayer and gave the stock a “buy” rating in a report on Monday, April 29th. Barclays set a €80.00 ($93.02) price target on Bayer and gave the stock a “buy” rating in a report on Monday, January 21st. HSBC set a €76.00 ($88.37) price target on Bayer and gave the stock a “neutral” rating in a report on Thursday, March 21st. Finally, Independent Research set a €52.50 ($61.05) price target on Bayer and gave the stock a “sell” rating in a report on Friday, March 29th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company. Bayer currently has a consensus rating of “Hold” and a consensus price target of €81.67 ($94.97).

BAYN opened at €56.45 ($65.64) on Tuesday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: What is a trade deficit?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.